Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Medicine (Baltimore) ; 100(25): e26382, 2021 Jun 25.
Article in English | MEDLINE | ID: mdl-34160414

ABSTRACT

RATIONALE: Multiple endocrine neoplasia type 1 (MEN1) is a rare tumor syndrome with an autosomal dominant inheritance, and genetic testing for MEN1 gene is important for both affected individuals and their relatives. We present a 2-person family affected by a germline c.1546dupC MEN1 mutation, and one of them had a full-spectrum of MEN-related endocrine tumors. PATIENT CONCERNS: A female patient aged 32 years presented with jejunal ulcer perforation due to gastrinoma. DIAGNOSES: We conducted genetic analysis and extensive biochemical/radiological evaluation for detecting other endocrine tumors. Multiple pancreatic neuroendocrine tumors (NETs), prolactinoma and primary hyperparathyroidism were diagnosed, and a frame-shift mutation, NM_130799.1:c.1546dupC (p.Arg516Profs∗15), was detected. One daughter of the proband, aged 12 years, had the same mutation for MEN1. INTERVENTION: She underwent pancreatic surgery for pancreatic NETs and total parathyroidectomy for primary hyperparathyroidism. OUTCOMES: After pancreatic surgery, long-term symptoms of epigastric soreness, acid belching, sweating, and palpitation in fasting were improved. Hypercalcemia was improved after parathyroidectomy and she was supplemented with oral calcium and vitamin D. Her daughter showed normal biochemical surveillance until 15 years of age. LESSONS: We report 2 people in a family affected by MEN1 with the heterozygous germline c.1546dupC mutation, a variant that should be surveilled for early development of full-blown MEN1-associated endocrine tumors.


Subject(s)
Multiple Endocrine Neoplasia Type 1/diagnosis , Neoplasms, Multiple Primary/diagnosis , Neuroendocrine Tumors/diagnosis , Proto-Oncogene Proteins/genetics , Adenoma/diagnosis , Adenoma/genetics , Adenoma/surgery , Adult , Child , Female , Frameshift Mutation , Gastrinoma/diagnosis , Gastrinoma/genetics , Gastrinoma/surgery , Genetic Testing , Germ-Line Mutation , Glucagonoma , Heterozygote , Humans , Hyperparathyroidism, Primary/diagnosis , Hyperparathyroidism, Primary/genetics , Hyperparathyroidism, Primary/surgery , Insulinoma , Multiple Endocrine Neoplasia Type 1/complications , Multiple Endocrine Neoplasia Type 1/genetics , Multiple Endocrine Neoplasia Type 1/surgery , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/surgery , Neuroendocrine Tumors/genetics , Neuroendocrine Tumors/surgery , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/surgery , Parathyroid Neoplasms/diagnosis , Parathyroid Neoplasms/genetics , Parathyroid Neoplasms/surgery , Parathyroidectomy , Prolactinoma/diagnosis , Prolactinoma/genetics , Prolactinoma/surgery
2.
Anticancer Res ; 40(7): 4029-4032, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32620648

ABSTRACT

The synchronous diagnosis of two or more primary malignancies in a patient is overall rare. This is a case report of a 70-year-old female with a history of skin squamous cell carcinoma presenting with occult hematochezia. Colonoscopy and biopsy results confirmed a microsatellite stable (MMS) adenocarcinoma in the ascending colon, and subsequent computed tomography (CT) scans identified a 3.2 cm right colonic mass and a 5.0 cm mass in the pancreatic body. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) confirmed the presence of pancreatic ductal adenocarcinoma (PDAC). The patient underwent neo-adjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin) chemotherapy prior to the simultaneous distal pancreatectomy and right hemicolectomy for both pancreatic and colonic tumors. The pathology diagnoses included moderately differentiated pancreatic ductal carcinoma (PDAC) with histiocyte-like features (tumor stage: ypT3N1M0) and moderately differentiated colonic adenocarcinoma, intestinal type (tumor stage: ypT3N0M0). To the best of our knowledge, this is the first documented case of synchronous primary colonic adenocarcinoma and PDAC in the English literature.


Subject(s)
Adenocarcinoma/diagnosis , Carcinoma, Pancreatic Ductal/diagnosis , Colonic Neoplasms/diagnosis , Neoplasms, Multiple Primary/diagnosis , Pancreatic Neoplasms/diagnosis , Adenocarcinoma/pathology , Aged , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Squamous Cell , Colonic Neoplasms/pathology , Female , Fluorouracil/therapeutic use , Humans , Irinotecan/therapeutic use , Leucovorin/therapeutic use , Neoplasms, Multiple Primary/pathology , Oxaliplatin/therapeutic use , Pancreatic Neoplasms/pathology , Skin Neoplasms
3.
Zhonghua Wai Ke Za Zhi ; 57(9): 666-672, 2019 Sep 01.
Article in Chinese | MEDLINE | ID: mdl-31474058

ABSTRACT

Objective: To analyze the status of domestic surgical treatment of synchronous peritoneal carcinomatosis from colorectal cancer in China. Methods: Clinicopathological data of patients who underwent surgery from October 2003 to October 2018 in 16 domestic medical centers was retrospectively analyzed. Excel database was created which covered 77 fields of 7 parts: baseline information of patients, laboratory tests, imaging tests, chemoradiotherapy information, intra-operative findings, postoperative pathology and follow-up data. The Wilcoxon rank-sum test was used for comparison of the measurement data between groups. The χ(2) test was used for comparison of the categorical data between groups. The survival curve was calculated by the Kaplan-Meier method. Results: Of the 1 003 patients, there were 575 male and 428 female patients with the age of (58.5±14.1) years (range: 18 to 92 years). In a total of 920 patients, the carcinoma of sigmoid colon was performed in 292 cases (31.8%) with the highest ratio. The proportion of patients with liver metastasis and lung metastasis were 27.9% (219/784) and 8.3% (64/769). Preoperative detection of carcino-embryonic antigen level was the most common method in China (87.74%, 880/1 003), and the positive rate was 64.5% (568/880). The correct rate of preoperative imaging tests was 40.7% (280/688). The ratio of peritoneal carcinomatosis index (PCI) scores between 0 and 10 was the highest (59.6%, 170/285). Two hundred and sixty-two (27.0%) patients were performed by totally laparoscopic operation in 971 patients. The resection of primary tumor was performed in 588 of the 817 patients (72.0%). In a total of 457 cases, 253 (55.4%) patients were performed cytoreduction which group scored completeness of cytoreduction (CCR) 0. The postoperative hyperthermic intraperitoneal chemotherapy was implemented in 70 of the 334 cases (21.0%). Among 1 003 cases, 562 cases (56.03%) had complete follow-up data and the median overall survival was 15 months. The primary tumor resection and the CCR scores were affected by the PCI scores. The patients underwent primary tumor resection (187/205 vs. 26/80, χ(2)=105.085, P=0.000) and the patients were performed cytoreduction which scored CCR 0 or CCR 1 (162/204 vs. 8/78, Z=-10.465, P=0.000) had significant difference between the groups of PCI<20 and ≥20. There was a close correlation between the surgical method and the CCR scores (Z=-3.246,P=0.001).When the maximum degree of tumor reduction was planned, most surgeons would choose laparotomy. The overall survival time was longer in patients with primary tumor resection (P=0.000). The median survival time was 18.6 months in the group of primary tumor resection. Conclusions: It is difficult to diagnose the synchronous peritoneal carcinomatosis from colorectal cancer before the operation. Primary tumor resection has an obvious effect to prolong the survival time. It is necessary to standardize the treatment of peritoneal metastasis.


Subject(s)
Colorectal Neoplasms/pathology , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/therapy , Peritoneal Neoplasms/diagnosis , Peritoneal Neoplasms/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , China , Colorectal Neoplasms/therapy , Combined Modality Therapy , Cytoreduction Surgical Procedures , Female , Humans , Hyperthermia, Induced , Laparoscopy , Male , Middle Aged , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/secondary , Retrospective Studies , Survival Rate , Young Adult
4.
Clin Transl Gastroenterol ; 10(2): e00006, 2019 02.
Article in English | MEDLINE | ID: mdl-30829920

ABSTRACT

Hepatocellular carcinoma (HCC) is characterized by high prevalence of multifocality. Multifocal HCC can arise synchronously or metachronously either from intrahepatic metastasis (IM) or multicentric occurrence (MO). To date, there have been no established criteria to accurately distinguish whether multifocal HCC originates from IM or MO. Histopathological features remain the most convenient strategy but with subjectivity and limited accuracy. Various molecular biological techniques involving assessment of TP53 mutation status, hepatitis B virus integration sites, and chromosomal alterations have been applied to determine the clonal origin. The introduction of next-generation sequencing facilitates a more comprehensive annotation of intertumor heterogeneity, resulting in more sensitive and accurate clonal discrimination. Generally, MO-HCC has better overall survival than IM-HCC after curative resection. Adjuvant antiviral treatment has been proved to decrease post-treatment recurrence probably by reducing MO-HCC recurrence, whereas adjuvant sorafenib treatment targeting prior micrometastasis failed to reduce IM-HCC recurrence. Recent studies recommended transcatheter arterial chemoembolization (TACE) and traditional Chinese medicine Huaier granule as effective adjuvant treatments probably by preventing IM and both types of recurrences respectively. Immunotherapy that inhibits immune checkpoint interaction may be an optimal choice for both MO- and IM-HCC. In the future, effective personalized therapy against multifocal HCC may be achieved.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , Liver/pathology , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Second Primary/diagnosis , Biomarkers, Tumor/genetics , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic/methods , Chemotherapy, Adjuvant/methods , Chromosome Aberrations , Clone Cells/pathology , Diagnosis, Differential , Hepatectomy , Hepatitis B virus/genetics , High-Throughput Nucleotide Sequencing , Humans , Liver/cytology , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Mutation , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/therapy , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/therapy , Patient Selection , Precision Medicine/methods , Sorafenib/therapeutic use , Treatment Outcome , Tumor Suppressor Protein p53/genetics
5.
J Cancer Res Ther ; 15(1): 250-251, 2019.
Article in English | MEDLINE | ID: mdl-30880786

ABSTRACT

Although cancers of rectum and kidney are common malignancies, the occurrence of primary synchronous neoplasms of these organs has been reported rarely. Very few case reports are available in literature till date. The relationship between these two events remains unclear, probably because of the rarity of the association. In this report, we describe incidentally detected renal cell carcinoma in an elderly man, during staging workup of rectal adenocarcinoma and both malignancies were surgically managed simultaneously with curative intent.


Subject(s)
Carcinoma, Renal Cell/therapy , Kidney Neoplasms/therapy , Neoplasms, Multiple Primary/therapy , Rectal Neoplasms/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/pathology , Chemoradiotherapy, Adjuvant/methods , Fluorouracil/therapeutic use , Humans , Kidney Neoplasms/diagnosis , Kidney Neoplasms/pathology , Leucovorin/therapeutic use , Male , Middle Aged , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/pathology , Nephrectomy , Organoplatinum Compounds/therapeutic use , Proctectomy , Rectal Neoplasms/diagnosis , Rectal Neoplasms/pathology , Treatment Outcome
6.
BMJ Case Rep ; 20182018 Mar 30.
Article in English | MEDLINE | ID: mdl-29602886

ABSTRACT

We report a case of a 46-year-old Vietnamese man who developed widespread, numerous and concurrent cutaneous squamous cell carcinomas (SCCs) in non-sun exposed skin areas after taking a traditional medicine (TM) formulation for chronic plaque psoriasis. The SCC lesions began to develop within 12-15 months after beginning the arsenic-containing TM. The patient experienced both acute and chronic symptoms consistent with arsenic exposure. Laboratory investigation of a collected hair sample showed a significant arsenic level. The TM formulation used by the patient was tested and demonstrated an extremely high concentration of arsenic.


Subject(s)
Arsenic Poisoning/complications , Carcinoma, Squamous Cell/chemically induced , Medicine, Traditional/adverse effects , Neoplasms, Multiple Primary/chemically induced , Psoriasis/drug therapy , Skin Neoplasms/chemically induced , Arsenic , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/surgery , Chronic Disease , Diagnosis, Differential , Humans , Male , Middle Aged , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/surgery , Skin Neoplasms/diagnosis , Skin Neoplasms/surgery , Time
8.
Curr Probl Cancer ; 41(6): 413-418, 2017.
Article in English | MEDLINE | ID: mdl-29129340

ABSTRACT

Multiple primary malignant neoplasms (MPMNs) are rare malignant neoplasms that simultaneously or successively occur in the same patient as 2 or more primary malignancies. Currently, an increasing number of cases are being reported. In general, MPMNs more commonly occur as 2 solid tumors or 2 hematological malignancies. Cases of MPMN that involve a solid tumor and a hematological malignancy are rare. Here, we report a case of synchronous colorectal cancer (CRC) and multiple myeloma (MM) with chest wall involvement. After reviewing the literature, we believe that there may be a distinct syndrome involving CRC and MM. The patient in our case study suffered refractory anemia following surgery and 2 cycles of chemotherapy. Initially, the anemia was considered to be a common manifestation of CRC in this patient. Interestingly, although he received a blood transfusion, his hemoglobin levels remained low. He later developed hematuria, proteinuria, multiple osteoporosis in the costal bones, and thrombocytopenia. These new symptoms drew our attention, and we considered a diagnosis of synchronous primary CRC and MM, with the anemia as a symptom of MM. Based on the results of a bone marrow aspirate, MM was confirmed. Therefore, when CRC is associated with refractory anemia, we should not only assume that anemia is a classical symptom of CRC, a result of chronic blood loss, nutritional deficiencies, or myelosuppression due to chemotherapy, but we should also consider that it may reflect the possibility of a coexisting hematologic malignancy. As the treatment of these 2 malignancies is different, early diagnosis and treatment based on definitive diagnosis as early as possible will be beneficial to overall prognosis.


Subject(s)
Adenocarcinoma/therapy , Anemia, Refractory/therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/therapy , Multiple Myeloma/therapy , Neoplasms, Multiple Primary/therapy , Adenocarcinoma/blood , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Anemia, Refractory/blood , Anemia, Refractory/diagnosis , Anemia, Refractory/etiology , Biopsy , Chemotherapy, Adjuvant/adverse effects , Colectomy , Colonoscopy , Colorectal Neoplasms/blood , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/pathology , Early Detection of Cancer , Fluorouracil/adverse effects , Humans , Leucovorin/adverse effects , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/diagnosis , Multiple Myeloma/pathology , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/pathology , Organoplatinum Compounds/adverse effects , Prognosis , Syndrome , Thoracic Wall/pathology , Tomography, X-Ray Computed
10.
World J Gastroenterol ; 23(1): 173-177, 2017 Jan 07.
Article in English | MEDLINE | ID: mdl-28104993

ABSTRACT

Multiple primary malignancy is defined as two or more malignancies detected in an individual person. In particular, synchronous quintuple primary malignancy is extremely rare. A 52-year-old male with anal pain and intermittent blood-tinged stool was diagnosed with malignancies in the stomach, jejunum, ascending colon, transverse colon and rectum. He underwent a subtotal gastrectomy, segmental resection of the jejunum and total protocolectomy with end ileostomy. The postoperative pathologic findings were moderate differentiated gastric adenocarcinoma (pT1bN0M0, pStageIA), combined adenocarcinoma and neuroendocrine carcinoma of the jejunum (pT3N0M0, pStageIIA), three mucinous adenocarcinoma of the ascending colon (pT3N0M0, pStageIIA), transverse colon (pT1N0M0, pStageI) and rectum (pT3N1aM0, pStageIIIB). The tumors did not lack MLH-1 and MSH-2 expression, as the markers (bat26, D5S346, bat25, D2S123) suggest MSI-H presence. Adjuvant chemoradiotherapy was started according to regimen, FOLFOX 4 for advanced rectal cancer. Six years post-operation, the patient is currently attending regular follow-ups without recurrence or metastasis.


Subject(s)
Adenocarcinoma, Mucinous/diagnosis , Colonic Neoplasms/diagnosis , Jejunal Neoplasms/diagnosis , Neoplasms, Multiple Primary/diagnosis , Rectal Neoplasms/diagnosis , Stomach Neoplasms/diagnosis , Adenocarcinoma, Mucinous/genetics , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Cancer Pain/etiology , Chemoradiotherapy, Adjuvant , Colectomy , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Colonic Neoplasms/therapy , Endoscopy, Gastrointestinal , Fluorouracil/therapeutic use , Gastrectomy/methods , Gastrointestinal Hemorrhage/etiology , Humans , Ileostomy , Jejunal Neoplasms/genetics , Jejunal Neoplasms/pathology , Jejunal Neoplasms/therapy , Leucovorin/therapeutic use , Male , Microsatellite Instability , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/therapy , Organoplatinum Compounds/therapeutic use , Positron Emission Tomography Computed Tomography , Rectal Neoplasms/genetics , Rectal Neoplasms/pathology , Rectal Neoplasms/therapy , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Tomography, X-Ray Computed
11.
Eur Ann Otorhinolaryngol Head Neck Dis ; 133(6): 383-386, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27474239

ABSTRACT

OBJECTIVES: To quantify and discuss the prevalence of unsuspected thyroid lymph node metastases discovered in specimens from neck dissection for head and neck squamous cell carcinoma (HNSCC) and discuss the impact on patient management. STUDY DESIGN: Retrospective study between May 2004 and January 2007. SETTING: University hospital. METHODS: Pathological analysis of cervical lymph node dissection performed during surgery for HNSCC in a total of 349 neck dissections in 266 consecutive patients. RESULTS: Twenty-one patients showed metastatic lymph nodes from thyroid cancer (prevalence 7.9%): 13 cases were metastatic from a papillary thyroid carcinoma and 8 cases from a follicular carcinoma. In 5 of the 21 patients, classical dissection was associated to recurrent nerve dissection and unilateral lobectomy; no thyroid carcinoma was found. Thirteen patients received radiotherapy for HNSCC. Follow-up comprised annual ultrasonographic examination of the neck and thyroid in these 21 patients. Total thyroidectomy was decided on in 5, with discovery of 3 micro-papillary thyroid carcinomas, in a single patient (complementary 131I treatment). No thyroid carcinomas were found for the other 4 patients. No patients died from thyroid carcinoma during follow-up (mean: 41 months). CONCLUSION: The prevalence of lymph node metastasis from thyroid carcinoma in cervical lymph node dissection during treatment of HNSCC seems higher (7.9%) than rates reported in the literature (0.3 to 1.6%). This may be due to the histopathological methods employed. Management of patients should be discussed in the light of thyroid ultrasonography and prognosis of HNSCC.


Subject(s)
Incidental Findings , Lymph Node Excision , Lymphatic Metastasis/diagnosis , Neck Dissection , Neoplasms, Multiple Primary/diagnosis , Thyroid Neoplasms/pathology , Adenocarcinoma, Follicular/pathology , Adenocarcinoma, Follicular/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Papillary/pathology , Carcinoma, Papillary/therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Female , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/surgery , Humans , Iodine Radioisotopes , Male , Middle Aged , Neoplasms, Multiple Primary/therapy , Retrospective Studies , Thyroid Neoplasms/therapy , Thyroidectomy
12.
Urologe A ; 55(7): 941-8, 2016 Jul.
Article in German | MEDLINE | ID: mdl-26943664

ABSTRACT

Bilateral oncocytosis along with multiple tumours in both kidneys represents a very rare pathology that is accompanied by diagnostic and therapeutic challenges. We report the case of a 60-year old male patient who underwent computer tomography with incidental detection of multiple bilateral and contrast enhancing renal tumours of different size. Subsequently the patient underwent nephron-sparing tumor resection, first on the right side and 4 weeks later on the left side. The histology of all removed tumors showed evidence of pure oncocytoma. There were no postoperative complications and renal function reached a stable state within 6 months follow-up. The major challenge regarding diagnostic process and therapy of this pathology is to distinguish benign oncocytoma from chromophobe renal cell carcinoma and hybrid tumours, which can all be associated with renal oncocytosis. Because of limitations concerning imaging processes and biopsy, all patients should undergo nephron-sparing surgery as far as possible. On the other hand alternative therapies should - regarding to therapy-associated morbidity and the basically benign prognosis of oncocytoma - be well discussed to obtain informed consent. In this case report different therapy options and the international literature concerning renal oncocytosis will be discussed.


Subject(s)
Adenoma, Oxyphilic/diagnosis , Adenoma, Oxyphilic/therapy , Hepatectomy/methods , Kidney Neoplasms/diagnosis , Kidney Neoplasms/therapy , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/therapy , Organ Sparing Treatments/methods , Adenoma, Oxyphilic/pathology , Clinical Decision-Making/methods , Diagnosis, Differential , Evidence-Based Medicine , Humans , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasms, Multiple Primary/pathology , Tomography, X-Ray Computed/methods , Treatment Outcome
13.
Can Oncol Nurs J ; 25(2): 226-36, 2015.
Article in English, French | MEDLINE | ID: mdl-26638292

ABSTRACT

Approximately one in two Canadians will develop some form of cancer, and some will live long enough to be diagnosed with multiple primary cancers. There is some indication that multiple primary cancer diagnoses negatively impact survivors' mental and physical status, and quality of life. Existing research studies do not fully capture the complexity of what it is like to have multiple primary cancer diagnoses. Accordingly, a qualitative study was conducted to elicit detailed descriptions of the lived experiences of having multiple primary cancer diagnoses. Participants included 10 individuals from Atlantic Canada with a history of two or more cancer diagnoses. Data were captured through semi-structured interviews and participant-generated photographs. Interviews were transcribed and reviewed for common meanings. Preliminary data analyses suggest that the essential meaning of having cancer multiple times is that cancer is "unwanted encore". This study yields findings that can provide empirically-based guidance to healthcare providers to help support cancer survivors in a more holistic way throughout the extended continuum of care and ultimately improve the health of individuals who have had multiple primary cancers.


Subject(s)
Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/psychology , Adult , Female , Humans , Male , Middle Aged
14.
Eur J Surg Oncol ; 41(7): 859-67, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25979624

ABSTRACT

AIM: The combination of surgery and chemotherapy (CTx) is increasingly accepted as an effective treatment for patients with colorectal liver metastases (CRLM). However, controversy exists whether all patients with resectable CRLM benefit from perioperative CTx. We investigated the impact on overall survival (OS) by neo-adjuvant CTx in patients with resectable CRLM, stratified by the clinical risk score (CRS) described by Fong et al. METHODS: Patients who underwent surgery for CRLM between January 2000 and December 2009 were included. We compared OS of patients with and without neo-adjuvant CTx stratified by the CRS. The CRS includes five prognosticators and defines two risk groups: low CRS (0-2) and high CRS (3-5). RESULTS: 363 patients (64% male) were included, median age 63 years (IQR 57-70). Prior to resection, 219 patients had a low CRS (neo-adjuvant CTx: N = 65) and 144 patients had a high CRS (neo-adjuvant CTx: N = 88). Median follow-up was 47 months (IQR 25-82). In the low CRS group, there was no significant difference in median OS between patients with and without CTx (65 months (95% CI 39-91) vs. 54 months (95% CI 44-64), P = 0.31). In the high CRS group, there was a significant difference in OS between patients with and without CTx (46 months (95% CI 24-68) vs. 33 month (95% CI 29-37), P = 0.004). CONCLUSION: In our series, patients with a high CRS benefit from neo-adjuvant CTx. In patients with a low risk profile, neo-adjuvant CTx might not be beneficial.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/pathology , Digestive System Surgical Procedures , Liver Neoplasms/drug therapy , Neoadjuvant Therapy/methods , Propensity Score , Aged , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Capecitabine , Chemotherapy, Adjuvant , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease-Free Survival , Drug Administration Schedule , Female , Fluorouracil/administration & dosage , Fluorouracil/analogs & derivatives , Humans , Irinotecan , Kaplan-Meier Estimate , Leucovorin/administration & dosage , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/prevention & control , Neoplasm Staging , Neoplasms, Multiple Primary/diagnosis , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , Treatment Outcome
15.
Tumori ; 100(4): 136e-9e, 2014.
Article in English | MEDLINE | ID: mdl-25296604

ABSTRACT

BACKGROUND: Nodal patterns of spread for breast cancer and melanoma have been extensively studied in the literature. The phenomenon of upper extremity melanoma and ipsilateral breast cancer has been previously reported. We describe a rare case of a simultaneous locoregional recurrence of both malignancies. CASE REPORT: A patient with a previous diagnosis of stage 1A melanoma of the left upper extremity at age 29 developed left breast invasive ductal carcinoma 1 year later. The patient underwent a wide local excision with negative margins for the melanoma and a partial mastectomy with axillary dissection followed by chemotherapy and radiation therapy for her breast cancer. Five years later she was diagnosed with a dual recurrence while 36 weeks pregnant. CONCLUSIONS: Regular follow-up according to the NCCN guidelines is critical in diagnosing a recurrence of malignancy. Pathologic analysis is paramount in dictating management strategies in rare cases of dual recurrence.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/therapy , Lymph Node Excision , Mastectomy, Segmental , Melanoma/secondary , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/therapy , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/therapy , Pregnancy Complications, Neoplastic/diagnosis , Pregnancy Complications, Neoplastic/therapy , Skin Neoplasms/pathology , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Arm , Axilla , Breast Neoplasms/diagnosis , Capecitabine , Carcinoma, Intraductal, Noninfiltrating/diagnosis , Carcinoma, Intraductal, Noninfiltrating/therapy , Chemotherapy, Adjuvant , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Fluorouracil/administration & dosage , Fluorouracil/analogs & derivatives , Humans , Interferons/administration & dosage , Mammaplasty , Mastectomy, Segmental/methods , Mastectomy, Simple , Neoplasm Grading , Neoplasms, Multiple Primary/pathology , Patient Care Team , Pregnancy , Pregnancy Complications, Neoplastic/pathology , Trastuzumab
16.
Langenbecks Arch Surg ; 399(2): 141-54, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24263684

ABSTRACT

BACKGROUND: Multifocal papillary thyroid carcinoma (MPTC) has been reported in literature in 18-87 % of cases. This paper aims to review controversies in the molecular pathogenesis, prognosis, and management of MPTC. METHODS: A review of English-language literature focusing on MPTC was carried out, and analyzed in an evidence-based perspective. Results were discussed at the 2013 Workshop of the European Society of Endocrine Surgeons devoted to surgery of thyroid carcinoma. RESULTS: Literature reports no prospective randomized studies; thus, a relatively low level of evidence may be achieved. CONCLUSIONS: MPTC could be the result of either true multicentricity or intrathyroidal metastasis from a single malignant focus. Radiation and familial nonmedullary thyroid carcinoma are conditions at risk of MPTC development. The prognostic importance of multifocal tumor growth in PTC remains controversial. Prognosis might be impaired in clinical MPTC but less or none in MPTC <1 cm. MPTC can be diagnosed preoperatively by FNAB and US, with low sensitivity for MPTC <1 cm. Total or near-total thyroidectomy is indicated to reduce the risk of local recurrence. Prophylactic central node dissection should be considered in patients with total tumor diameter >1 cm, or in cases with high number of cancer foci. Completion thyroidectomy might be necessary when MPTC is diagnosed after less than near-total thyroidectomy. Radioactive iodine ablation should be considered in selected patients with MPTC at increased risk of recurrence or metastatic spread.


Subject(s)
Adenocarcinoma, Papillary/surgery , Neoplasms, Multiple Primary/surgery , Thyroid Neoplasms/surgery , Adenocarcinoma, Papillary/diagnosis , Adenocarcinoma, Papillary/genetics , Adenocarcinoma, Papillary/pathology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Chernobyl Nuclear Accident , Combined Modality Therapy , DNA Mutational Analysis , Disease Progression , Europe , Neck Dissection , Neoplasm Staging , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/pathology , Neoplasms, Radiation-Induced/diagnosis , Neoplasms, Radiation-Induced/genetics , Neoplasms, Radiation-Induced/pathology , Neoplasms, Radiation-Induced/surgery , Prognosis , Radiotherapy, Adjuvant , Risk Factors , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Thyroidectomy
17.
Chirurgia (Bucur) ; 108(1): 43-5, 2013.
Article in English | MEDLINE | ID: mdl-23464768

ABSTRACT

INTRODUCTION: SCC have an incidence of 1,8% up to 12,4% and could have more simultaneous localizations. MATERIAL AND METHOD: Between January 2004 and January 2011, 214 patients with CRC have been operated on in our ward; from those, eight patients had multiple colorectal neoplasms. RESULTS: The majority of SCC (six cases) was hospitalized under emergency status, with incomplete or complete bowel obstruction through colonic obstructive tumour. The favourite localizations were on the sigmoid (six tumours) and the transverse colon (four tumours). The diagnosis was preoperatively assessed in three cases by colonoscopy and barium enema, intraoperative in four cases, postoperative in one case. Curative operations were performed in five cases and palliative operations in three. Immediate postsurgical evolution was good, long time evolution was marked by the complications of the primary disease. Out of five patients that were long term monitored, three have a five year survival, one has survived for three years and one deceased within a nine month period after surgery, with multiple metastases. CONCLUSIONS: Preoperative diagnosis of synchronous lesions can be difficult (emergency hospitalized patient, incomplete bowel preparation, bowel obstruction or intestinal bleeding) and the colonoscopy exam can be incomplete. Rigorous intraoperative colonic examination is necessary in order to diagnose synchronous lesions and avoid surgical reintervention.


Subject(s)
Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/surgery , Intestinal Obstruction/diagnosis , Intestinal Obstruction/surgery , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/surgery , Aged , Colectomy , Colorectal Neoplasms/complications , Colorectal Neoplasms/mortality , Female , Humans , Incidence , Intestinal Obstruction/etiology , Intestinal Obstruction/mortality , Male , Middle Aged , Neoplasms, Multiple Primary/complications , Neoplasms, Multiple Primary/mortality , Retrospective Studies , Romania/epidemiology , Survival Rate , Treatment Outcome
18.
Endocr J ; 60(4): 423-9, 2013.
Article in English | MEDLINE | ID: mdl-23268928

ABSTRACT

A 46 year-old male presented with persistently high level of serum parathyroid hormone (PTH), despite successful resection of an oxyphilic cell parathyroid adenoma of the left lower gland. Renal function and serum calcium were normal, leading to vitamin D deficiency being considered. Tc99m-sestamibi parathyroid scintigraphy showed no capitation, but a cervical ultrasound demonstrated an increase in the lower parathyroids. Surgery confirmed that the right gland was normal but the left corresponded to parathyroid carcinoma. The patient developed severe hypocalcemia, with PTH values being consistent with hypoparathyroidism for a few months. However, a progressive increase in calcium and PTH serum levels indicated recurrence of disease. Tc99m-sestamibi scintigraphy demonstrated hyperfixation in topography of the left inferior parathyroid and the patient was subjected to a third and more extensive surgery, with removal of lymph nodes and adjacent thyroid tissue. Serum calcium and PTH remained elevated, requiring loop diuretics and intravenous bisphosphonates to control hypercalcemia. Cervical radiotherapy was implemented as adjuvant therapy. After two months the patient complained of dyspnea, and a CT scan of the chest demonstrated areas of parenchymal condensation, suggestive of actinic pneumonitis. At the 2-year follow-up no major issues were evident.


Subject(s)
Adenoma, Oxyphilic/diagnosis , Carcinoma/diagnosis , Delayed Diagnosis , Diagnostic Errors , Neoplasms, Multiple Primary/diagnosis , Parathyroid Neoplasms/diagnosis , Adenoma, Oxyphilic/physiopathology , Adenoma, Oxyphilic/radiotherapy , Adenoma, Oxyphilic/surgery , Brazil , Carcinoma/physiopathology , Carcinoma/radiotherapy , Carcinoma/surgery , Humans , Hyperparathyroidism, Primary/etiology , Hypocalcemia/etiology , Male , Middle Aged , Neoplasms, Multiple Primary/physiopathology , Neoplasms, Multiple Primary/radiotherapy , Neoplasms, Multiple Primary/surgery , Parathyroid Neoplasms/physiopathology , Parathyroid Neoplasms/radiotherapy , Parathyroid Neoplasms/surgery , Radiotherapy, Adjuvant , Recurrence , Treatment Outcome
19.
Klin Padiatr ; 224(6): 339-47, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23143761

ABSTRACT

Retinoblastoma affects approximately 40 children in Germany per year. Most children are diagnosed early with localized intraocular disease, and the overall survival rate exceeds 95%. However, the prognosis of metastasized retinoblastoma remains poor. In 40% of the patients, retinoblastoma occurs bilaterally and, especially for these children, the salvage of the eye and visual function is of major importance. The variety of conservative treatment options for localized retinoblastoma includes laser coagulation, thermotherapy, cryotherapy, brachytherapy and chemotherapy. While systemic chemotherapy has nearly completely replaced external beam radiotherapy in the primary treatment of intraocular retinoblastoma, intra-arterial, intravitreal and periocular application of chemotherapy was also shown to be effective in treating intraocular retinoblastoma in case series. Genetic testing is an integral part of the routine diagnostics of all patients. Available tumor material should be analyzed to detect mutational mosaicism, that affects >10% of children with unilateral retinoblastoma. Genetic testing also identifies children with heritable (50% of patients) retinoblastoma. These children have a genetic predisposition for second malignancies. For this reason, late effects are an increasing concern and the care of patients with retinoblastoma requires a multidisciplinary approach to tailor therapy and long-term follow-up. Multicenter clinical trials are being developed to evaluate evidence-based treatment concepts for localized and metastasized retinoblastoma to improve survival rates and quality of life of children with retinoblastoma.


Subject(s)
Retinal Neoplasms/diagnosis , Retinal Neoplasms/therapy , Retinoblastoma/diagnosis , Retinoblastoma/therapy , Vision Disorders/diagnosis , Vision Disorders/prevention & control , Vision Disorders/therapy , Child , Combined Modality Therapy , Cooperative Behavior , Disease Progression , Early Diagnosis , Genes, Retinoblastoma/genetics , Genetic Testing , Humans , Interdisciplinary Communication , Neoplasm Staging , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/therapy , Prognosis , Retinal Neoplasms/genetics , Retinal Neoplasms/mortality , Retinal Neoplasms/pathology , Retinoblastoma/genetics , Retinoblastoma/mortality , Retinoblastoma/pathology , Survival Rate , Vision Disorders/mortality , Vision Disorders/pathology
SELECTION OF CITATIONS
SEARCH DETAIL